Sporozoite challenge study to assess protective efficacy of two prime-boost malaria vaccine candidates: ChAd63 MVA endocing ME-TRAP and the same viral vectors encoding CS

These vaccines consist of viruses (ChAd63 and MVA) that have been genetically modified so (i) they cannot replicate in humans and (ii) they include parts of the malaria parasite; Plasmodium falciparum (CS and ME-TRAP). The hope is that these vaccines will induce immune responses in vaccines that are able to prevent malaria.
This proposed study will compare how effective ChAd63-MVA CS is at preventing malaria infection in UK volunteers following the malaria challenge compared to ChAd63-MVA ME-TRAP.
The study will be conducted at the University of Oxford’s Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford, UK, and the Wellcome Trust Clinical Research Facility in Southampton, UK. The malaria challenge will take place at the insectary at Imperial College (Infection and Immunity Section) in London, UK.

Study type: Interventional
Enrollment: 30 participants
Primary purpose: Basic Science
Allocation:Randomized
Interventional Model: Parallel assignment
Masking : Open label
NCT number: NCT01623557
Phase: Phase I/II

Clinical trial registration

Vaccines

Apr 2012 — Nov 2012

United Kingdom